30 Nintedanib (BIBF 1120) + docetaxel as second-line...

Lung Cancer 2014 / 01 Vol. 83

30 Nintedanib (BIBF 1120) + docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial

Reck, M., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., Barrueco, J., Gaschler-Markefski, B., Kaiser, R., Novello, S.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
83
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/S0169-5002(14)70031-5
Date:
January, 2014
File:
PDF, 48 KB
english, 2014
Conversion to is in progress
Conversion to is failed